J 2018

A pilot data analysis of a metabolomic HPLC-MS/MS study of patients with COPD

NOVOTNA, B., M. ABDEL-HAMID, V. KOBLIZEK, Michal SVOBODA, Karel HEJDUK et. al.

Základní údaje

Originální název

A pilot data analysis of a metabolomic HPLC-MS/MS study of patients with COPD

Autoři

NOVOTNA, B. (203 Česká republika, garant), M. ABDEL-HAMID (414 Kuvajt), V. KOBLIZEK (203 Česká republika), Michal SVOBODA (203 Česká republika, domácí), Karel HEJDUK (203 Česká republika, domácí), V. REHACEK (203 Česká republika), J. BIS (203 Česká republika) a F. SALAJKA (203 Česká republika)

Vydání

ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, WROCLAW, WROCLAW MEDICAL UNIV, 2018, 1899-5276

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10103 Statistics and probability

Stát vydavatele

Polsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.227

Kód RIV

RIV/00216224:14110/18:00103470

Organizační jednotka

Lékařská fakulta

UT WoS

000432226900014

Klíčová slova anglicky

amino acids; chronic obstructive pulmonary disease; liquid chromatography-tandem mass spectrometry; carnitine; metabolomics

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 9. 2. 2019 19:50, Soňa Böhmová

Anotace

V originále

Background. Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with multiple clinical faces. Metabolomic profiling studies small molecules present in biological samples by combined use of chromatography with mass spectrometry. Objectives. The goal of our work was to perform a high performance liquid chromatography combined with tandem mass spectrometry (HPLC-MS/MS) metabolomic study to compare the concentrations of metabolites in COPD patients and in controls. Material and methods. Participants were recruited at the University Hospital, Hradec Kralove, Czech Republic, with the approval of the ethics committee. The analysis of blood samples was performed at Health Sciences Center (HSC) in Kuwait. The blood samples were analyzed for concentrations of acylcarnitines and amino acids by high performance liquid chromatography (Waters 2690 HPLC; Waters, Milford, USA) and a triple-quadruple tandem mass spectrometer (Quattro LC, Micromass, Manchester, United Kingdom). Results. Groups of 10 subjects with COPD and 10 healthy controls were analyzed. Carnitine analysis showed that the free carnitine to acylcarnitine ratio (CO/AC ratio) was significantly lower in COPD (0.58 mu M/L) compared to the controls (0.73 mu M/L; p = 0.002). The mean C8/C2 ratio in the COPD group was significantly higher (0.03 mu M/L) - in the control group it was 0 mu M/L (p = 0.03). Amino acid analysis showed lower levels of phenylalanine in the COPD group (22.05 mu M/L) compared to the controls (30.05 mu M/L; p = 0.008). The alanine concentrations were significantly lower in the COPD group (173 mu M/L) than in the control group (253 mu M/L; p = 0.001). The pyroglutamate levels were higher in COPD (1.58 mu M/L) than in the controls (1 mu M/L; p = 0.040). Conclusions. The carnitine and acylcarnitine levels in COPD subjects in this study possibly indicate a predisposition to atherosclerosis as a result of inadequate p-oxidation of fatty acids and show the presence of oxidative stress. Furthermore, the high sensitivity to changes in circulating amino acid levels may allow us to detect subclinical malnutrition and take early preventative interventions such as nutritional supplementation and patient education.